Home  Media Press releases 2001
|
|
|
| 19 October 2001 | 2001-10-19T00:00:00.0000000+01:00 |
| ZD1839 IRESSA DATA
AstraZeneca is encouraged by the positive results from IDEAL 1 (IRESSA Dose Evaluation in Advanced Lung cancer), the first pivotal study of ZD1839 (IRESSA) in non-small-cell-lung-cancer (NSCLC) and looks forward to the presentation of these phase II data at the 12th AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" in Miami, USA. Whilst the abstract of the data is available on www.aacr.org, the full results from IDEAL 1 will not be presented until Thursday, November 1, 2001, and the requirements of the AACR-NCI-EORTC scientific committee preclude discussion of the data presented in the abstract by the authors or the company until the day of the presentation. | AstraZeneca will be issuing press information announcing the results from IDEAL I on Thursday, November 1, 2001. |
Steve Brown
+44 (0)20 7304 5033
Emily Denny
+44 (0)20 7304 5034
|
|
Mina Blair-Robinson
+44 (0)20 7304 5084
Jorgen Winroth
+1 609 896 4148
|
Iressa is a trademark, property of the AstraZeneca group of companies.
|
|
|
|